Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy

World Journal of Hepatology

Volumn 7, Issue 3, 2015, Pages 539-547

  López Serrano, Pilar ^a   de La Fuente Briongos, Elsa ^a   Alonso, Elisa Carrera ^b   Pérez Calle, Jose Lázaro ^a   Rodríguez, Conrado Fernández ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^b HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

Author keywords

Anti tumor necrosis factor; Corticosteroids; Dermatologic diseases; Hepatitis B virus; Immunosuppressants; Inflammatory bowel disease; Prophylaxis; Rheumatic disease

Indexed keywords

EID: 84928946809     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i3.539     Document Type: Article

References (83)

1. Shouval D, Shibolet O. Immunosuppression and HBV reactivation. Semin Liver Dis 2013; 33: 167-177 [PMID: 23749673 DOI:10.1055/s-0033-1345722]
2. Koskinas J, Tampaki M, Doumba PP, Rallis E. Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in a hepatitis B surface-antigen-negative anti-HBs-positive patient. Br J Dermatol 2013; 168: 679-680 [PMID: 23121260 DOI: 10.1111/ bjd.12120]
3. Huang ML, Xu XT, Shen J, Qiao YQ, Dai ZH, Ran ZH. Prevalence and factors related to hepatitis B and C infection in inflammatory bowel disease patients in China: a retrospective study. J Crohns Colitis 2014; 8: 282-287 [PMID: 24067604 DOI: 10.1016/ j.crohns.2013.08.017]
4. Stroffolini T, Guadagnino V, Chionne P, Procopio B, Mazzuca EG, Quintieri F, Scerbo P, Giancotti A, Nisticò S, Focà A, Tosti ME, Rapicetta M. A population based survey of hepatitis B virus infection in a southern Italian town. Ital J Gastroenterol Hepatol 1997; 29: 415-418 [PMID: 9494849]
5. Sansone S, Guarino M, Castiglione F, Rispo A, Auriemma F, Loperto I, Rea M, Caporaso N, Morisco F. Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease. World J Gastroenterol 2014; 20: 3516-3524 [PMID:24707134 DOI: 10.3748/wjg.v20.i13.3516]
6. Gisbert JP, Chaparro M, Esteve M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33:619-633 [PMID: 21416659 DOI: 10.1111/j.1365-2036.2010.04570]
7. Biancone L, Pavia M, Del Vecchio Blanco G, D'Incà R, Castiglione F, De Nigris F, Doldo P, Cosco F, Vavassori P, Bresci GP, Arrigoni A, Cadau G, Monteleone I, Rispo A, Fries W, Mallardi B, Sturniolo GC, Pallone F. Hepatitis B and C virus infection in Crohn's disease. Inflamm Bowel Dis 2001; 7: 287-294 [PMID: 11720317 DOI:10.1097/00054725-200111000-00002]
8. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006; 43: S173-S181 [PMID: 16447285 DOI: 10.1002/ hep.20956]
9. Loras C, Saro C, Gonzalez-Huix F, Mínguez M, Merino O, Gisbert JP, Barrio J, Bernal A, Gutiérrez A, Piqueras M, Calvet X, Andreu M, Abad A, Ginard D, Bujanda L, Panés J, Torres M, Fernández-Bañares F, Viver JM, Esteve M. Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol 2009; 104: 57-63 [PMID: 19098850 DOI: 10.1038/ajg.2008.4]
10. Chevaux JB, Nani A, Oussalah A, Venard V, Bensenane M, Belle A, Gueant JL, Bigard MA, Bronowicki JP, Peyrin-Biroulet L. Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France. Inflamm Bowel Dis 2010; 16: 916-924 [PMID: 19885908 DOI:10.1002/ibd.21147]
11. Kim ES, Cho KB, Park KS, Jang BI, Kim KO, Jeon SW, Kim EY, Yang CH, Kim WJ. Prevalence of hepatitis-B viral markers in patients with inflammatory bowel disease in a hepatitis-B-endemic area: inadequate protective antibody levels in young patients. J Clin Gastroenterol 2014; 48: 553-558 [PMID: 24162170 DOI:10.1097/01.mcg.0000436435.75392.23]
12. Conway R, Doran MF, O'Shea FD, Crowley B, Cunnane G. The impact of hepatitis screening on diagnosis and treatment in rheumatoid arthritis. Clin Rheumatol 2014; 33: 1823-1827 [PMID:24728880 DOI: 10.1007/s10067-014-2612-4]
13. Zou CJ, Zhu LJ, Li YH, Mo YQ, Zheng DH, Ma JD, Ou-Yang X, Pessler F, Dai L. The association between hepatitis B virus infection and disease activity, synovitis, or joint destruction in rheumatoid arthritis. Clin Rheumatol 2013; 32: 787-795 [PMID: 23340833 DOI: 10.1007/s10067-013-2170-1]
14. Zheng B, Li T, Lin Q, Huang Z, Wang M, Deng W, Liao Z, Gu J. Prevalence of hepatitis B surface antigen in patients with ankylosing spondylitis and its association with HLA-B27: a retrospective study from south China. Rheumatol Int 2012; 32: 2011-2016 [PMID:21479602 DOI: 10.1007/s00296-011-1934-7]
15. Watanabe R, Ishii T, Kobayashi H, Asahina I, Takemori H, Izumiyama T, Oguchi Y, Urata Y, Nishimaki T, Chiba K, Komatsuda A, Chiba N, Miyata M, Takagi M, Kawamura O, Kanno T, Hirabayashi Y, Konta T, Ninomiya Y, Abe Y, Murata Y, Saito Y, Ohira H, Harigae H, Sasaki T. Prevalence of hepatitis B virus infection in patients with rheumatic diseases in Tohoku area:a retrospective multicenter survey. Tohoku J Exp Med 2014; 233:129-133 [PMID: 24898712]
16. Cohen AD, Weitzman D, Birkenfeld S, Dreiher J. Psoriasis associated with hepatitis C but not with hepatitis B. Dermatology 2010; 220: 218-222 [PMID: 20185894 DOI: 10.1159/000286131]
17. López-Serrano P, Pérez-Calle JL, Sánchez-Tembleque MD. Hepatitis B and inflammatory bowel disease: role of antiviral prophylaxis. World J Gastroenterol 2013; 19: 1342-1348 [PMID:23538480 DOI: 10.3748/wjg.v19.i9.1342]
18. Beaugerie L, Gerbes AL. Liver dysfunction in patients with IBD under immunosuppressive treatment: do we need to fear? Gut 2010; 59: 1310-1311 [PMID: 20833661 DOI: 10.1136/gut.2010.217331]
19. Manzano-Alonso ML, Castellano-Tortajada G. Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy. World J Gastroenterol 2011; 17:1531-1537 [PMID: 21472116 DOI: 10.3748/wjg.v17.i12]
20. Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases:assessment and preventive strategies. Ann Rheum Dis 2006; 65:983-989 [PMID: 16627542]
21. Tur-Kaspa R, Shaul Y, Moore DD, Burk RD, Okret S, Poellinger L, Shafritz DA. The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. Virology 1988; 167: 630-633 [PMID:3201757]
22. Herbein G, O'Brien WA. Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis. Proc Soc Exp Biol Med 2000; 223:241-257 [PMID: 10719836 DOI: 10.1046/j.1525-1373.2000.22335.x]
23. Kasahara S, Ando K, Saito K, Sekikawa K, Ito H, Ishikawa T, Ohnishi H, Seishima M, Kakumu S, Moriwaki H. Lack of tumor necrosis factor alpha induces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes. J Virol 2003; 77: 2469-2476 [PMID: 12551985 DOI: 10.1128/JVI.77.4.2469-2476.2003]
24. Morisco F, Castiglione F, Rispo A, Stroffolini T, Vitale R, Sansone S, Granata R, Orlando A, Marmo R, Riegler G, Vecchi M, Biancone L, Caporaso N. Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease. Dig Liver Dis 2011; 43 Suppl 1: S40-S48 [PMID: 21195371 DOI: 10.1016/ S1590-8658(10)60691-3]
25. Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, Cottone M, de Ridder L, Doherty G, Ehehalt R, Esteve M, Katsanos K, Lees CW, Macmahon E, Moreels T, Reinisch W, Tilg H, Tremblay L, Veereman-Wauters G, Viget N, Yazdanpanah Y, Eliakim R, Colombel JF. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2014; 8: 443-468 [PMID: 24613021 DOI: 10.1016/ j.crohns.2013.12.013]
26. Hanbali A, Khaled Y. Incidence of hepatitis B reactivation following Rituximab therapy. Am J Hematol 2009; 84: 195 [PMID:19140189 DOI: 10.1002/ajh.21343]
27. Flowers MA, Heathcote J, Wanless IR, Sherman M, Reynolds WJ, Cameron RG, Levy GA, Inman RD. Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy. Ann Intern Med 1990; 112: 381-382 [PMID: 2306066 DOI: 10.7326/0003-4819-112-5-381]
28. Wendling D, Auge B, Bettinger D, Lohse A, Le Huede G, Bresson-Hadni S, Toussirot E, Miguet JP, Herbein G, Di Martino V. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 2005; 64: 788-789 [PMID:15834064 DOI: 10.1136/ard.2004.031187]
29. Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 2004; 63 Suppl 2: ii18-ii24 [PMID: 15479865]
30. Verhelst X, Orlent H, Colle I, Geerts A, De Vos M, Van Vlierberghe H. Subfulminant hepatitis B during treatment with adalimumab in a patient with rheumatoid arthritis and chronic hepatitis B. Eur J Gastroenterol Hepatol 2010; 22: 494-499 [PMID: 20306568]
31. Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. J Rheumatol 2003; 30: 1624-1625 [PMID:12858469]
32. Oshima Y, Tsukamoto H, Tojo A. Association of hepatitis B with antirheumatic drugs: a case-control study. Mod Rheumatol 2013; 23: 694-704 [PMID: 22802011 DOI: 10.1007/s10165-012-0709-7]
33. Lee YH, Bae SC, Song GG. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing antitumor necrosis factor therapy or DMARDs. Int J Rheum Dis 2013; 16: 527-531 [PMID: 24164839 DOI: 10.1111/1756-185X.12154]
34. Nakamura J, Nagashima T, Nagatani K, Yoshio T, Iwamoto M, Minota S. Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs. Int J Rheum Dis 2014 Apr 4; Epub ahead of print [PMID:24698305 DOI: 10.1111/1756-185X]
35. Esteve M, Saro C, González-Huix F, Suarez F, Forné M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004; 53: 1363-1365 [PMID: 15306601 DOI: 10.1136/gut.2004.040675]
36. Ojiro K, Naganuma M, Ebinuma H, Kunimoto H, Tada S, Ogata H, Iwao Y, Saito H, Hibi T. Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab. J Gastroenterol 2008; 43:397-401 [PMID: 18592158]
37. del Valle García-Sánchez M, Gómez-Camacho F, Poyato-González A, Iglesias-Flores EM, de Dios-Vega JF, Sancho-Zapatero R. Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection. Inflamm Bowel Dis 2004; 10: 701-702 [PMID: 15472541 DOI: 10.1097/00054725-200409000-00035]
38. Esteve M, Loras C, González-Huix F. Lamivudine resistance and exacerbation of hepatitis B in infliximab-treated Crohn's disease patient. Inflamm Bowel Dis 2007; 13: 1450-1451 [PMID: 17712837 DOI: 10.1002/ibd.20202]
39. Loras C, Gisbert JP, Mínguez M, Merino O, Bujanda L, Saro C, Domenech E, Barrio J, Andreu M, Ordás I, Vida L, Bastida G, González-Huix F, Piqueras M, Ginard D, Calvet X, Gutiérrez A, Abad A, Torres M, Panés J, Chaparro M, Pascual I, Rodriguez-Carballeira M, Fernández-Bañares F, Viver JM, Esteve M. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut 2010; 59: 1340-1346 [PMID: 20577000 DOI: 10.1136/gut.2010.208413]
40. Garcia-Vidal C, Rodríguez-Fernández S, Teijón S, Esteve M, Rodríguez-Carballeira M, Lacasa JM, Salvador G, Garau J. Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention. Eur J Clin Microbiol Infect Dis 2009; 28: 331-337 [PMID: 18797940 DOI: 10.1007/s10096-008-0628-x]
41. Conde-Taboada A, Muñoz JP, Muñoz LC, López-Bran E. Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection. J Am Acad Dermatol 2009; 60:1077-1080 [PMID: 19467387 DOI: 10.1016/j.jaad.2008.09.057]
42. Pérez-Alvarez R, Díaz-Lagares C, García-Hernández F, Lopez-Roses L, Brito-Zerón P, Pérez-de-Lis M, Retamozo S, Bové A, Bosch X, Sanchez-Tapias JM, Forns X, Ramos-Casals M. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore) 2011; 90: 359-371 [PMID: 22033451 DOI: 10.1097/ MD.0b013e3182380a76]
43. Navarro R, Vilarrasa E, Herranz P, Puig L, Bordas X, Carrascosa JM, Taberner R, Ferrán M, García-Bustinduy M, Romero-Maté A, Pedragosa R, García-Diez A, Daudén E. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting. Br J Dermatol 2013; 168:609-616 [PMID: 22985451 DOI: 10.1111/bjd.12045]
44. Purnak S, Purnak T. Hepatitis B virus reactivation after ustekinumab treatment. Br J Dermatol 2014; 170: 477-478 [PMID:24032639 DOI: 10.1111/bjd.12612]
45. Lledó JL, Fernández C, Gutiérrez ML, Ocaña S. Management of occult hepatitis B virus infection: an update for the clinician. World J Gastroenterol 2011; 17: 1563-1568 [PMID: 21472122]
46. Matsumoto T, Marusawa H, Dogaki M, Suginoshita Y, Inokuma T. Adalimumab-induced lethal hepatitis B virus reactivation in an HBsAg-negative patient with clinically resolved hepatitis B virus infection. Liver Int 2010; 30: 1241-1242 [PMID: 20345703 DOI:10.1111/j.1478-3231.2010.02238.x]
47. Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H, Enomoto M, Inaba M, Nakatani T, Hino M, Kawada N. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy:evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol 2011; 46: 556-564 [PMID: 21246383 DOI: 10.1007/ s00535-010-0367-5]
48. Cassano N, Mastrandrea V, Principi M, Loconsole F, De Tullio N, Di Leo A, Vena GA. Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease. J Biol Regul Homeost Agents 2011; 25: 285-289 [PMID: 21880218 DOI: 10.1111/j.1365-4632.2011.05100.x]
49. Dixon WG, Kezouh A, Bernatsky S, Suissa S. The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested casecontrol study. Ann Rheum Dis 2011; 70: 956-960 [PMID: 21285116 DOI: 10.1136/ard.2010.144741]
50. Update on adult immunization. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1991; 40: 1-94 [PMID: 1956371]
51. Shepherd JE, Grabenstein JD. Immunizations for high-risk populations. J Am Pharm Assoc (Wash) 2001; 41: 839-849; quiz 923-925 [PMID: 11765109]
52. Campos-Outcalt D. Immunization update: the latest ACIP recommendations. J Fam Pract 2014; 63: 137-140 [PMID:24701599]
53. Greenberg JD, Reed G, Kremer JM, Tindall E, Kavanaugh A, Zheng C, Bishai W, Hochberg MC. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis 2010; 69: 380-386 [PMID: 19359261 DOI: 10.1136/ ard.2008.089276]
54. Aberra FN, Lewis JD, Hass D, Rombeau JL, Osborne B, Lichtenstein GR. Corticosteroids and immunomodulators:postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology 2003; 125: 320-327 [PMID:12891531 DOI: 10.1016/S0016-5085(03)00883-7]
55. Serradori T, Germain A, Scherrer ML, Ayav C, Perez M, Romain B, Palot JP, Rohr S, Peyrin-Biroulet L, Bresler L. The effect of immune therapy on surgical site infection following Crohn's Disease resection. Br J Surg 2013; 100: 1089-1093 [PMID: 23649458 DOI:10.1002/bjs.9152]
56. Wands JR, Chura CM, Roll FJ, Maddrey WC. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 1975; 68: 105-112 [PMID: 1054319]
57. Nakanishi K, Ishikawa M, Nakauchi M, Sakurai A, Doi K, Taniguchi Y. Antibody to hepatitis B e positive hepatitis induced by withdrawal of steroid therapy for polymyositis: response to interferon-alpha and cyclosporin A. Intern Med 1998; 37: 519-522 [PMID: 9678685 DOI: 10.2169/internalmedicine]
58. Cheng J, Li JB, Sun QL, Li X. Reactivation of hepatitis B virus after steroid treatment in rheumatic diseases. J Rheumatol 2011; 38:181-182 [PMID: 21196589 DOI: 10.3899/jrheum.100692]
59. Zanati SA, Locarnini SA, Dowling JP, Angus PW, Dudley FJ, Roberts SK. Hepatic failure due to fibrosing cholestatic hepatitis in a patient with pre-surface mutant hepatitis B virus and mixed connective tissue disease treated with prednisolone and chloroquine. J Clin Virol 2004; 31: 53-57 [PMID: 15288614 DOI: 10.1016/ j.jvc.2004.02.013]
60. Bae JH, Sohn JH, Lee HS, Park HS, Hyun YS, Kim TY, Eun CS, Jeon YC, Han DS. A fatal case of hepatitis B virus (HBV) reactivation during long-term, very-low-dose steroid treatment in an inactive HBV carrier. Clin Mol Hepatol 2012; 18: 225-228 [PMID:22893874 DOI: 10.3350/cmh.2012.18.2.225]
61. Li X, Tian J, Wu J, He Q, Li H, Han F, Li Q, Chen Y, Ni Q, Chen J. A comparison of a standard-dose prednisone regimen and mycophenolate mofetil combined with a lower prednisone dose in Chinese adults with idiopathic nephrotic syndrome who were carriers of hepatitis B surface antigen: a prospective cohort study. Clin Ther 2009; 31: 741-750 [PMID: 19446147 DOI: 10.1016/ j.clinthera.2009.04.011]
62. Yang CH, Wu TS, Chiu CT. Chronic hepatitis B reactivation: a word of caution regarding the use of systemic glucocorticosteroid therapy. Br J Dermatol 2007; 157: 587-590 [PMID: 17596145]
63. Xuan D, Yu Y, Shao L, Wang J, Zhang W, Zou H. Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy--a report of long-term follow-up of serial cases and literature review. Clin Rheumatol 2014; 33: 577-586 [PMID: 24343455 DOI: 10.1007/s10067-013-2450-9]
64. Colbert C, Chavarria A, Berkelhammer C. Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease. Inflamm Bowel Dis 2007; 13: 1453-1454 [PMID: 17600380 DOI: 10.1002/ibd.20216]
65. Zeitz J, Mullhaupt B, Fruehauf H, Rogler G, Vavricka SR. Hepatic failure due to hepatitis B reactivation in a patient with ulcerative colitis treated with prednisone. Hepatology 2009; 50: 653-654 [PMID: 19575458 DOI: 10.1002/hep.23035]
66. Harris DM. Some properties of beclomethasone dipropionate and related steroids in man. Postgrad Med J 1975; 51 Suppl 4: 20-25 [PMID: 1105513]
67. Nos P, Hinojosa J, Gomollón F, Ponce J. Budesonide in inflammatory bowel disease: a meta-analysis. Med Clin (Barc) 2001; 116: 47-53 [PMID: 11181269]
68. Seow CH, Benchimol EI, Griffiths AM, Otley AR, Steinhart AH. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2008; (3): CD000296 [PMID: 18646064 DOI:10.1002/14651858.CD000296.pub3]
69. Gross V, Bunganic I, Belousova EA, Mikhailova TL, Kupcinskas L, Kiudelis G, Tulassay Z, Gabalec L, Dorofeyev AE, Derova J, Dilger K, Greinwald R, Mueller R. 3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial. J Crohns Colitis 2011; 5: 129-138 [PMID: 21453882 DOI: 10.1016/ j.crohns.2010.11.006]
70. Papi C, Aratari A, Moretti A, Mangone M, Margagnoni G, Koch M, Capurso L. Oral beclomethasone dipropionate as an alternative to systemic steroids in mild to moderate ulcerative colitis not responding to aminosalicylates. Dig Dis Sci 2010; 55: 2002-2007 [PMID: 19937467 DOI: 10.1007/s10620-009-0962-6]
71. Nunes T, Barreiro-de Acosta M, Marin-Jiménez I, Nos P, Sans M. Oral locally active steroids in inflammatory bowel disease. J Crohns Colitis 2013; 7: 183-191 [PMID: 22784947 DOI: 10.1016/ j.crohns.2010.07.003]
72. Lichtenstein GR, Bengtsson B, Hapten-White L, Rutgeerts P. Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysis. Aliment Pharmacol Ther 2009; 29: 643-653 [PMID: 19035972 DOI: 10.1111/j.1365-2036.2008.03891.x]
73. Domènech E, Esteve M, Gomollón F, Hinojosa J, Panés J, Obrador A, Gassull MA. [GETECCU-2005 recommendations for the use of infliximab (Remicade) in inflammatory bowel disease]. Gastroenterol Hepatol 2005; 28: 126-134 [PMID: 15771858]
74. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662 [PMID: 19714720 DOI: 10.1002/ hep.23190]
75. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185 [PMID: 22436845 DOI: 10.1016/j.jhep.2012.02.010]
76. Liaw Y, Kao J, Piratvisuth T, Yuen Chan H, Chien R, Liu C, Gane E, Locarnini S, Lim S, Han K, Amarapurkar D, Cooksley G, Jafri W, Mohamed R, Hou J, Chuang W, Lesmana L, Sollano J, Suh D, Omata M. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012; 6: 531-561 [DOI: 10.1007/s12072-012-9365-4]
77. Buti M, García-Samaniego J, Prieto M, Rodríguez M, Sánchez-Tapias JM, Suárez E, Esteban R. [Consensus document of the Spanish Association for the Study of the Liver on the treatment of hepatitis B infection (2012)]. Gastroenterol Hepatol 2012; 35:512-528 [PMID: 22749508 DOI: 10.1016/j.gastrohep.2012.04.006]
78. Sagnelli E, Pisaturo M, Martini S, Filippini P, Sagnelli C, Coppola N. Clinical impact of occult hepatitis B virus infection in immunosuppressed patients. World J Hepatol 2014; 6: 384-393 [PMID: 25018849 DOI: 10.4254/wjh.v6.i6.384]
79. Mastroianni CM, Lichtner M, Citton R, Del Borgo C, Rago A, Martini H, Cimino G, Vullo V. Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World J Gastroenterol 2011; 17: 3881-3887 [PMID: 22025876 DOI:10.3748/wjg.v17.i34.3881]
80. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007; 45: 1056-1075 [PMID: 17393513 DOI: 10.1002/hep.21627]
81. Toruner M, Loftus EV, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, Colombel JF, Egan LJ. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 929-936 [PMID: 18294633 DOI:10.1053/j.gastro.2008.01.012]
82. Vallet-Pichard A, Pol S. Hepatitis B virus treatment beyond the guidelines: special populations and consideration of treatment withdrawal. Therap Adv Gastroenterol 2014; 7: 148-155 [PMID:25057295]
83. Sacco R, Bertini M, Bresci G, Romano A, Altomare E, Capria A. Entecavir for hepatitis B virus flare treatment in patients with Crohn's disease. Hepatogastroenterology 2010; 57: 242-245 [PMID:20583421]